The price of seizure control: Dynorphins in interictal and postictal psychosis

Psychiatry Research

Volumn 151, Issue 1-2, 2007, Pages 139-143

  Bortolato, Marco ^a   Solbrig, Marylou V ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dynorphin; Interictal psychosis; Kappa opioid receptors; Postictal psychosis

Indexed keywords

DYNORPHIN; KAPPA OPIATE RECEPTOR;

DISEASE CONTROL; HIPPOCAMPUS; HUMAN; INTERICTAL PSYCHOSIS; NONHUMAN; POSTICTAL PSYCHOSIS; PRIORITY JOURNAL; PROTEIN SECRETION; PSYCHOSIS; REVIEW; SEIZURE;

ANIMALS; ANTICONVULSANTS; DYNORPHINS; EPILEPSY, TEMPORAL LOBE; HIPPOCAMPUS; HUMANS; KINDLING, NEUROLOGIC; PSYCHOTIC DISORDERS; RECEPTORS, OPIOID, KAPPA;

EID: 34247396650     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2006.11.004     Document Type: Review

References (66)

1. Akanuma N., Kanemoto K., Adachi N., Kawasaki J., Ito M., and Onuma T. Prolonged postictal psychosis with forced normalization (Landolt) in temporal lobe epilepsy. Epilepsy and Behavior 6 (2005) 456-459
2. Albertson T.E., Joy R.M., and Startk L.G. Modification of kindled amygdaloid seizures by opiate agonists and antagonists. Journal of Pharmacology and Experimental Therapeutics 228 (1984) 620-627
3. Arvidsson U., Riedl M., Chakrabarti S., Vulchanova L., Lee J.H., Nakano A.H., Lin X., Loh H.H., Law P.-Y., Wessendorf M.W., and Elde R. The k-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids. Proceedings of the National Academy of Science of the United States of America 92 (1995) 5062-5066
4. Bast T., and Feldon J. Hippocampal modulation of sensorimotor processes. Progress in Neurobiology 70 (2003) 319-345
5. Bausch S.B., Esteb T.M., Terman G.W., and Chavkin C. Administration and endogenously released kappa opioids decrease pilocarpine-induced seizures and seizure-induced histopathology. Journal of Pharmacology and Experimental Therapeutics 284 (1998) 1147-1155
6. Becker A., Braun H., Schroder H., Grecksch G., and Hollt V. Effects of enadoline on the development of pentylenetetrazol kindling, learning performance, and hippocampal morphology. Brain Research 823 (1999) 191-197
7. Bortolato M., Aru G.N., Frau R., Orru M., Fa M., Manunta M., Puddu M., Mereu G., and Gessa G.L. Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats. Biological Psychiatry 57 (2005) 1550-1558
8. Chavkin C., James I.F., and Goldstein A. Dynorphin is a specific endogenous ligand of the k opioid receptor. Science 215 (1982) 413-415
9. Chen L., Gu Y., and Huang L.Y. The opioid peptide dynorphin directly blocks NMDA receptor channels in the rat. Journal of Physiology 482 (1995) 575-581
10. Chen L., Gu Y., and Huang L.Y. The mechanism of action for the block of NMDA receptor channels by the opioid peptide dynorphin. Journal of Neuroscience 15 (1995) 4602-4611
11. Coutureau E., Galani R., Jarrard L.E., and Cassel J.C. Selective lesions of the entorhinal cortex, the hippocampus, or the fimbria-fornix in rats: a comparison of effects on spontaneous and amphetamine-induced locomotion. Experimental Brain Research 131 (2000) 381-392
12. De Lanerolle N.C., Kim J.H., Robbins R.J., and Spencer D.D. Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. Brain Research 495 (1989) 387-395
13. De Lanerolle N.C., Williamson A., Meredith C., Kim J.H., Tabuteau H., Spencer D.D., and Brines M.L. Dynorphin and the kappa 1 ligand [3H]U69,593 binding in the human epileptogenic hippocampus. Epilepsy Research 28 (1997) 189-205
14. Denney D., and Stevens J.R. Clozapine and seizures. Biological Psychiatry 37 (1995) 427-433
15. Devinsky O. Therapy for neurobehavioral disorders in epilepsy. Epilepsia 45 (2004) 34-40
16. Drake C.T., Patterson T.A., Simmons M.L., Chavkin C., and Milner T.A. Kappa opioid receptor-like immunoreactivity in guinea pig brain: ultrastructural localization in presynaptic terminals in hippocampal formation. Journal of Comparative Neurology 370 (1996) 377-395
17. Engel Jr. J., and la Rocha L. Interictal behavioral disturbances: a search for molecular substrates. Epilepsy Research. Supplement 9 (1992) 341-349
18. Flor-Henry P. Determinants of psychosis in epilepsy: laterality and forced normalization. Biological Psychiatry 18 (1983) 1045-1057
19. Halim N.D., and Swerdlow N.R. Distributed neurodegenerative changes 2-28 days after ventral hippocampal excitotoxic lesions in rats. Brain Research 873 (2000) 60-74
20. Harrison M.B., Shumate M.D., and Lothman E.W. Opioid peptide expression in models of chronic temporal lobe epilepsy. Neuroscience 65 (1995) 785-795
21. Hauser K.F., Aldrich J.V., Anderson K.J., Bakalkin G., Christie M.J., Hall E.D., Knapp P.E., Scheff S.W., Singh I.N., Vissel B., Woods A.S., Yakovleva T., and Shippenberg T.S. Pathobiology of dynorphins in trauma and disease. Frontiers in Bioscience 10 (2005) 216-235
22. Heikkila L., Rimon R., and Terenius L. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Research 34 (1990) 229-236
23. Henriksen S.J., Chouvet G., McGinty J., and Bloom F.E. Opioid peptides in the hippocampus: anatomical and physiological considerations. Annals of the New York Academy of Sciences 398 (1982) 207-220
24. Hong J.S., McGinty J.F., Grimes L., Kanamatsu T., Obie J., and Mitchell C.L. Seizure-induced alterations in the metabolism of hippocampal opioid peptides suggest opioid modulation of seizure-related behaviors. National Institute on Drug Abuse Research Monograph Series 82 (1988) 48-66
25. Houser C.R., Miyashiro J.E., Swartz B.E., Walsh G.O., Rich J.R., and Delgado-Escueta A.V. Altered patterns of dynorphin immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy. Journal of Neuroscience 10 (1990) 267-282
26. Iadarola M.J., Ofri D., and Kleinman J.E. Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients. Life Science 48 (1991) 1919-1930
27. Kanner A.M. Recognition of the various expressions of anxiety, psychosis, and aggression in epilepsy. Epilepsia 45 (2004) 22-27
28. Krishnamoorthy E.S., Trimble M.R., Sander J.W., and Kanner A.M. Forced normalization at the interface between epilepsy and psychiatry. Epilepsy and Behavior 3 (2002) 303-308
29. Landolt H. Some clinical electroencephalographical correlations in epileptic psychoses (twilight states). EEG Clinical Neurophysiology 5 (1953) 122
30. Lindstrom L.H. Clinical and biological markers for outcome in schizophrenia: a review of a longitudinal follow-up study in Uppsala schizophrenia research project. Neuropsychopharmacology 14 (1996) 23S-26S
31. Logsdail S.J., and Toone B.K. Post-ictal psychoses. A clinical and phenomenological description. British Journal of Psychiatry 152 (1988) 246-252
32. Ma J., and Leung L.S. Schizophrenia-like behavioral changes after partial hippocampal kindling. Brain Research 997 (2004) 111-118
33. Madamba S.G., Schweitzer P., and Siggins G.R. Dynorphin selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism. Journal of Neurophysiology 82 (1999) 1768-1775
34. Manocha A., Mediratta P.K., and Sharma K.K. Studies on the anticonvulsant effect of U50488H on maximal electroshock seiziure in mice. Pharmacology, Biochemistry and Behavior 76 (2003) 111-117
35. Mansour A., Fox C.A., Meng F., Akil H., and Watson S.J. K1 receptor mRNA distribution in the rat CNS: comparison to k receptor binding and prodynorphin mRNA. Molecular and Cellular Neurosciences 5 (1994) 124-144
36. Meduna L. Ueber experimentelle Campherepilepsie. Archiv fuer Psychiatrie 102 (1934) 333-339
37. Moore S.D., Madamba S.G., Schweitzer P., and Siggins G.R. Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro. Journal of Neuroscience 14 (1994) 809-820
38. Pakalnis A., Drake Jr. M.E., John K., and Kellum J.B. Forced normalization. Acute psychosis after seizure control in seven patients. Archives of Neurology 44 (1987) 289-292
39. Pfeiffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986) 774-776
40. Prendergast J., Spira P., and Schnieden V. Post-ictal psychosis: an unusual clinical entity. Australian and New Zealand Journal of Psychiatry 33 (1999) 433-435
41. Przewlocka B., Machelska H., and Lason W. Kappa opioid receptor agonists inhibit pilocarpine-induced seizures and toxicity in the mouse. European Neuropsychopharmacology 4 (1994) 527-533
42. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., Ernsberger P., and Rothman R.B. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Science of the United States of America 99 (2002) 11934-11939
43. Roy A.K., Rajesh S.V., Iby N., Jose J.M., and Sarma G.R. A study of epilepsy-related psychosis. Neurology India 51 (2003) 359-360
44. Simmons M.L., and Chavkin C. K-opioid receptor activation of a dendrotoxin-sensitive potassium channel mediates presynaptic inhibition of mossy fiber neurotransmitter release. Molecular Pharmacology 50 (1996) 80-85
45. Simonato M., and Romualdi P. Dynorphin and epilepsy. Progress in Neurobiology 50 (1996) 557-583
46. Solbrig M.V., Adrian R., Baratta J., Lauterborn J.C., and Koob G.F. Kappa opioid control of seizures briproduced by a virus in an animal model. Brain 129 (2006) 642-654
47. Solbrig M.V., Adrian R., Chang D.Y., and Perng G.C. Viral risk factor for seizures: pathobiology of dynorphin in herpes simplex viral (HSV-1) seizures in an animal model. Neurobiology of Disease 23 (2006) 612-620
48. Stevens J.R. Clozapine: the yin and yang of seizures and psychosis. Biological Psychiatry 37 (1995) 425-426
49. Stevens J.R. Epilepsy, schizophrenia and the extended amygdala. Annals of the New York Academy of Sciences 877 (1999) 548-561
50. Stogmann E., Zimprich A., Baumgartner C., Aull-Watschinger S., Hollt V., and Zimprich F. A functional polymorphism in the prodynorphin gene promoter is associated with temporal lobe epilepsy. Annals of Neurology 51 (2002) 260-263
51. Swerdlow N.R., Taaid N., Halim N., Randolph E., Kim Y.K., and Auerbach P. Hippocampal lesions enhance startle-gating disruptive effects of apomorphine in rats: a parametric assessment. Neuroscience 96 (2000) 523-536
52. Tang Q., Gandhoke R., Burritt A., Hruby V.J., Porreca F., and Lai J. High-affinity interaction of (des-Tyrosyl)Dynorphin A(2-17) with NMDA receptors. Journal of Pharmacology and Experimental Therapeutics 291 (1999) 760-765
53. Tebartz van Elst L.H., Baeumer D., Lemieux L., Woermann F.G., Koepp M., Krishnamoorthy S., Thompson P.J., Ebert D., and Trimble M.R. Amygdala pathology in psychosis of epilepsy: a magnetic resonance imaging study in patients with temporal lobe epilepsy. Brain 125 (2002) 140-149
54. Tempel A., and Zukin R.S. Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proceedings of the National Academy of Science of the United States of America 84 (1987) 4308-4312
55. Tortella F.C., Robles L., and Holaday J.W. U50,488, a highly selective kappa opioid: anticonvulsant profile in rats. Journal of Pharmacology and Experimental Therapeutics 237 (1986) 49-53
56. VonVoigtlander P.F., Hall E.D., Ochoa M.C., Lewis R.A., and Triezenberg H.J. U-54494A: a unique anticonvulsant related to kappa opioid agonists. Journal of Pharmacology and Experimental Therapeutics 243 (1987) 542-547
57. Wagner J.J., Terman G.W., and Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 363 (1993) 451-454
58. Walsh S.L., Strain E.C., Abreu M.E., and Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157 (2001) 151-162
59. Weisskopf M.G., Zalutsky R.A., and Nicoll R.A. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fiber synapses and modulates long-term potentiation. Nature 362 (1993) 423-427
60. Wolf P. Acute behavioral symptomatology at disappearance of epileptiform EEG abnormality. Paradoxical or "forced" normalization. Advances in Neurology 55 (1991) 127-142
61. Wolf P., and Trimble M.R. Biological antagonism and epileptic psychosis. British Journal of Psychiatry 146 (1985) 272-276
62. Xiong Z.G., Zhu X.M., Chu X.P., Minami M., Hey J., Wei W.L., MacDonald J.F., Wemmie J.A., Price M.P., Welsh M.J., and Simon R.P. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 118 (2004) 687-698
63. Yajima Y., Narita M., Takahashi-Nakano Y., Misawa M., Nagase H., Mizoguchi H., Tseng L.F., and Suzuki T. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Research 862 (2000) 120-126
64. Yermolaieva O., Leonard A.S., Schnizler M.K., Abboud F.M., and Welsh M.J. Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. Proceedings of the National Academy of Science of the United States of America 101 (2004) 6752-6757
65. Zhang A.Z., Zhou G.Z., Xi G.F., Gu N.F., Xia Z.Y., Yao J.L., Chang J.K., Webber R., and Potkin S. Lower CSF level of dynorphin(1-8) immunoreactivity in schizophrenic patients. Neuropeptides 5 (1985) 553-556
66. Zukin R.S., Eghbali M., Olive D., Unterwald E.M., and Tempel A. Characterization and visualization of rat and guinea pig brain k opioid receptors: evidence for k1 and k2 opioid receptors. Proceedings of the National Academy of Science of the United States of America 85 (1988) 4061-4065